NCT00448240 2025-03-18
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Henry Ford Health System
Phase 2/3 Terminated
Clinical Trials
3 trialsNCT02926638 2020-03-19
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network
Phase 2/3 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated